ArticleFrontiers in pharmacology2020

Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients.

Dehua Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.